Advertisement


Patrick Schöffski, MD, MPH, on RCC: Final Results of the EORTC 90101 CREATE Trial

2018 Genitourinary Cancers Symposium

Advertisement

Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification (Abstract 580).



Related Videos

Prostate Cancer

Robert G. Bristow, MD, PhD, on Prostate Cancer: Keynote Lecture

Robert G. Bristow, MD, PhD, of Manchester Cancer Research Centre, discusses germline and somatic mutations; new ways to generate biomarkers that may describe tumor complexity; and ...

Kidney Cancer
Immunotherapy

Sumanta K. Pal, MD, on RCC: Results From Two Clinical Trials

Sumanta K. Pal, MD, of the City of Hope Comprehensive Cancer Center, discusses phase III study findings from IMmotion151, which looked at atezolizumab plus bevacizumab vs sunitinib...

Prostate Cancer

Eric J. Small, MD, on Prostate Cancer: Results From the SPARTAN Trial

Eric J. Small, MD, of the University of California, San Francisco, discusses phase III findings on apalutamide vs placebo in patients with nonmetastatic castration-resistant prosta...

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: Abstract Roundup

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he chaired on prostate cancer, which included discussion of daily vs weekly image-guided radiotherapy;...

Bladder Cancer
Immunotherapy

Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis

Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abst...

Advertisement

Advertisement



;
Advertisement